Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Research Articles

A novel agonistic antibody to human death receptor 4 induces apoptotic cell death in various tumor cells without cytotoxicity in hepatocytes

Eun-Sil Sung, Kyung-Jin Park, Seung-Hyun Lee, Yoon-Seon Jang, Sang-Koo Park, Yoo-Hoi Park, Won-Jae Kwag, Myung-Hee Kwon and Yong-Sung Kim
Eun-Sil Sung
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kyung-Jin Park
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Seung-Hyun Lee
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yoon-Seon Jang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sang-Koo Park
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yoo-Hoi Park
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Won-Jae Kwag
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Myung-Hee Kwon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yong-Sung Kim
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1535-7163.MCT-09-0235 Published August 2009
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Additional Files
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Biochemical characterization of mouse anti-DR4 AY4 mAb. A, size exclusion elution profile of AY4 injected at 0.5 mg/mL (≈3.3 μmol/L) and monitored at 280 nm. The arrows indicate the elution positions of molecular weight standards (alcohol dehydrogenase, 150 kDa; bovine serum albumin, 66 kDa; ovalbumin, 45 kDa), including blue dextran 2000 (∼2,000 kDa) as a void volume marker. B, binding specificity of AY4 and TRAIL analyzed by ELISA. ELISA plates were coated with 10 μg/mL of DR4-ECD, DR5-ECD, DcR1-ECD, DcR2-ECD, mTR-ECD, or CD95-ECD and then incubated with 1 μg/mL TRAIL (black columns) or 1 μg/mL AY4 (white columns). C, kinetic interactions of AY4 with DR4-ECD determined by SPR analyses. SPR sensograms were obtained from injections of serially diluted DR4-ECD at 100, 50, 25, 12.5, 6.25, and 3.125 nmol/L (solid lines from top to bottom) over an AY4 immobilized surface at 2,400 response units. The injection of DR5-ECD (long dashed line), DcR1-ECD (dotted line), and DcR2-ECD (dash-dotted line) at 2 μmol/L exhibited negligible binding to AY4. D, competitive ELISA. Binding activity of AY4 (1 μg/mL) to DR4 in the presence of serially diluted TRAIL (from 800 to 1.56 μg/mL) was assessed in plates coated with DR4-ECD. B and D, bars, SD.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    AY4 alone induces cell death of various human cancer cells through cell surface–expressed DR4 without significant cytotoxicity on normal human hepatocytes. A and B, cell killing activities of TRAIL (left) and anti-DR4 AY4 mAb (right) in various TRAIL-sensitive and TRAIL-resistant tumor cells (A) and in normal human hepatocytes (B). Cells were incubated with the indicated concentrations of TRAIL or AY4 for 24 h. C, inhibition of cell death induced by TRAIL (left) or AY4 (right) by the soluble competitor DR4-ECD (black columns) or DR5-ECD (white columns). Cells were treated with 0.5 μg/mL TRAIL (≈30 nmol/L) or 10 μg/mL AY4 (≈67 nmol/L) for 24 h in the presence of the indicated concentrations (0, 0.04, and 1 μg/mL) of DR4-ECD or DR5-ECD. Bars, SD.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    Dual staining of Annexin V-FITC and PI for Jurkat, Ramos, and HL60 cells treated with medium only for 12 h, 0.5 μg/mL TRAIL for 3.5 h, or 10 μg/mL AY4 for 6 and 12 h (as indicated in each panel). Samples were then analyzed by flow cytometry. In the dot plots, Annexin V-FITC+/PI− cells (bottom right quadrant, % shown) and Annexin V-FITC+/PI+ cells (top right quadrant, % shown) are considered as “early apoptotic” and “dead” cells, respectively.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    AY4 induces caspase-dependent apoptotic cell death of AY4-sensitive cells. A, detection of proteolytic processing of apoptotic molecules by Western blotting analyses in HCT116 (left), Jurkat (middle), and HL60 cells (right), which were untreated (control) or treated with either 0.5 μg/mL TRAIL for 3.5 h or the indicated concentrations of AY4 for 24 h. Proforms (black arrowhead) and cleaved forms (white arrowhead) of caspase-8, Bid, caspase-9, caspase-3, and poly(ADP-ribose) polymerase (PARP) are indicated. The β-actin protein levels are included as a control for protein loading. B and C, effects of a pan-caspase inhibitor, Z-VAD-fmk, on the cell viability of HCT116, H460, Ramos, and Jurkat cells treated with either TRAIL (B) or AY4 (C). Cells untreated (black columns) or pretreated (white columns) with Z-VAD-fmk (10 μmol/L) for 0.5 h were further incubated with either 0.5 μg/mL TRAIL or 10 μg/mL AY4 for 24 h. Bars, SD.

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5.

    AY4-stimulated DR4 signaling requires FADD and caspase-8 and can transduce the extrinsic and/or intrinsic apoptotic pathways depending on the cell types. A, cell viability of Jurkat wild-type and its FADD-deficient (FADD-def.), caspase-8–deficient (Caspase-8-def.), or RIP1-deficient (RIP1-def.) cells, which were incubated with the indicated concentrations of TRAIL (left) or AY4 (right) for 24 h. B, HCT116 and its Bax-deficient (Bax−/−) or p53-deficient (p53−/−) cells were incubated with the indicated concentrations of TRAIL (left) or AY4 (right) for 24 h. C, effects of a caspase-9 inhibitor, Z-LEHD-fmk, on the cell viability of HCT116, H460, Ramos, Jurkat, and HL60 cells treated with either TRAIL (left) or AY4 (right). Cells untreated (black columns) or pretreated (white columns) for 0.5 h with Z-LEHD-fmk (20 μmol/L) were further incubated with either 0.5 μg/mL TRAIL or 10 μg/mL AY4 for 24 h. Bars, SD.

  • Figure 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 6.

    Antitumor effect of anti-DR4 AY4 on growth of preestablished H460 tumors in athymic nude mice. A to C, comparisons of tumor growth during the treatment (A) and isolated tumor weight (B) and tumor size (C) at the end of treatment (after 22 d of tumor inoculation) between mice treated with AY4 and IC antibody. After preestablishing of H460 cells with volume of ∼100 mm3 (day 7), mice (n = 6 per group) were administered i.v. with five doses of AY4 or IC antibody at a single dosage of 5 mg/kg/injection (100 μg/injection) every 3 d from day 7 (as indicated by white arrowheads). Bars, SD. Significance was determined using the Student's t test versus control IC–treated group. *, P < 0.0001; **, P < 0.01.

Additional Files

  • Figures
  • Supplementary Data

    Files in this Data Supplement:

    • Supplementary Data
PreviousNext
Back to top
Molecular Cancer Therapeutics: 8 (8)
August 2009
Volume 8, Issue 8
  • Table of Contents
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
A novel agonistic antibody to human death receptor 4 induces apoptotic cell death in various tumor cells without cytotoxicity in hepatocytes
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
A novel agonistic antibody to human death receptor 4 induces apoptotic cell death in various tumor cells without cytotoxicity in hepatocytes
Eun-Sil Sung, Kyung-Jin Park, Seung-Hyun Lee, Yoon-Seon Jang, Sang-Koo Park, Yoo-Hoi Park, Won-Jae Kwag, Myung-Hee Kwon and Yong-Sung Kim
Mol Cancer Ther August 1 2009 (8) (8) 2276-2285; DOI: 10.1158/1535-7163.MCT-09-0235

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
A novel agonistic antibody to human death receptor 4 induces apoptotic cell death in various tumor cells without cytotoxicity in hepatocytes
Eun-Sil Sung, Kyung-Jin Park, Seung-Hyun Lee, Yoon-Seon Jang, Sang-Koo Park, Yoo-Hoi Park, Won-Jae Kwag, Myung-Hee Kwon and Yong-Sung Kim
Mol Cancer Ther August 1 2009 (8) (8) 2276-2285; DOI: 10.1158/1535-7163.MCT-09-0235
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • PX-478 Radiosensitization in Pancreatic Cancer
  • Metronomic Gemcitabine Inhibits Pancreatic Cancer
  • p53-Deficient Cells Are More Sensitive to Plk1 Inhibitor
Show more Research Articles
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement